RE:RE:Theralase AUA Pesentation at annual meetingHi Legit62, I will strongly repeat the remarks I made about the clinicians meeting which also applies to this AUA presentation and that is there are very few people that attend these meetings that are retail stock buyers. If anything they invest into is done through their financial advisors and probably mutual funds or hedge funds. A person attending in todays medical environment is swamped with patients, these people don't have the time or desire to be spending hours looking up data. I do think a few will be impressed enough by Theralase to make a call to their financial advisor to buy into this stock but it won't be until they get back home or after they see the next set of numbers.
What will really move this stock is the news media and more buy ratings from Financial Institutions, all this in my opinion could happen with our expectations of BTD, AA and advancements in partnerships and yes GBM, NSCLC or moves in Covid-19 vaccine/therapeutics.